Cited by 114Digital Mental Health InterventionsSubstance Abuse Treatment and OutcomesMobile Health and mHealth Applications

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.

A randomized controlled trial of a therapeutic relational agent for reducing substance misuse during the COVID-19 pandemic

Open access

Abstract

BACKGROUND: The COVID-19 pandemic disrupted access to treatment for substance use disorders (SUDs), while alcohol and cannabis retail sales increased. During the pandemic, we tested a tailored digital health solution, Woebot-SUDs (W-SUDs), for reducing substance misuse. METHODS: In a randomized controlled trial, we compared W-SUDs for 8 weeks to a waitlist control. U.S. adults (N = 180) who screened positive for substance misuse (CAGE-AID>1) were enrolled June-August 2020. The primary outcome was the change in past-month substance use occasions from baseline to end-of-treatment (EOT). Study retention was 84%. General linear models tested group differences in baseline-to-EOT change scores, adjusting for baseline differences and attrition. RESULTS: At baseline, the sample (age M = 40, SD = 12, 65% female, 68% non-Hispanic white) averaged 30.2 (SD = 18.6) substance occasions in the past month. Most (77%) reported alcohol problems, 28% cannabis, and 45% multiple substances; 46% reported moderate-to-severe depressive symptoms. Treatment participants averaged 920 in-app text messages (SD = 892, Median = 701); 96% of completed lessons were rated positively; and 88% would recommend W-SUDs. Relative to waitlist, W-SUDs participants significantly reduced past-month substance use occasions (M = -9.1, SE = 2.0 vs. M = -3.3, SE = 1.8; p = .039). Secondary substance use and mood outcomes did not change significantly by group; however, reductions in substance use occasions correlated significantly with increased confidence and fewer substance use problems, cravings, depression and anxiety symptoms, and pandemic-related mental health effects (p-value<.05). CONCLUSIONS: W-SUDs was associated with significant reductions in substance use occasions. Reduction in substance use occasions was associated with better outcomes, including improved mental health. W-SUDs satisfaction was high.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.drugalcdep.2021.108986

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A study of the chatbot app Woebot, used to help reduce substance misuse, found that greater frequency of use (numbers of in-app text) was not significantly associated with a reduction in substance use occasions (r = 0.23).

    “A study of the chatbot app Woebot, used to help reduce substance misuse, found that greater frequency of use (numbers of in-app text) was not significantly associated with a reduction in substance use occasions (r = 0.23) (50).”

    From Digital Therapeutic Alliance With Fully Automated Mental Health Smartphone Apps: A Narrative Review (2022) · cites this paper as [50]

    The Results section ('W-SUDs use and acceptability') reports that the correlation between in-app text count and reduction in substance use occasions was not statistically significant (p = .06). However, it gives r = −.23, not the claimed r = 0.23. (LLM, conf=0.92)

    Experimental — accuracy not yet measured
  • A study of the app Woebot, used to reduce substance misuse during COVID-19, found that the bond subscale rating was higher than task and goal subscales ratings.

    “A study of the app Woebot (a therapeutic chatbot that delivers CBT), which was used to reduce substance misuse during the COVID-19, found that the bond subscale rating was higher than task and goal subscales ratings (50).”
  • Two studies showed that users could potentially build a bond with chatbot apps.

    “However, two studies showed that users could potentially build a bond with chatbot apps.”
  • Clarke et al. measured number of program interactions (i.e., logins), number of modules completed, and frequency of self-monitoring, while Prochaska et al. measured days used, in-app text messages, and completed modules.

    “Clarke et al. (14) measured number of program interactions (i.e., logins), number of modules completed, and frequency of self-monitoring, while Prochaska et al. (50) measured days used, in-app text messages, and completed modules.”
  • Previous research demonstrated Woebot's efficacy to reduce substance abuse among adults.

    “Previous research demonstrated Woebot’s feasiblity and acceptability as well as efficacy to reduce (1) depression and anxiety among young adults [20], (2) depression among postpartum women [32,33], and (3) substance abuse among adults [34,35].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

1 of the 34 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Metadata

Authors
Prochaska, J. J., Vogel, E. A., Chieng, A., Baiocchi, M., Maglalang, D. D., Pajarito, S., Weingardt, K. R., Darcy, A., & Robinson, A.
Affiliations
  • Stanford Medicine (US)
  • Stanford University (US)
  • Woebot Health (United States) (US)
Corresponding author
Prochaska, Judith J.
Venue
Drug and Alcohol Dependence
Publisher
Elsevier BV
Published
2021-10
Volume
227
Pages
108986
ISSN
0376-8716 (ISSN-L)
OpenAlex
W3196926390
Cited by
113
References
34
Citations by year
2026: 42 · 2025: 17 · 2024: 24 · 2023: 22 · 2022: 8
FWCI
12.12
Type
journal article
Language
en
Open access
Locations
  • Drug and Alcohol Dependence (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institutes of Health (44-D048712, 32HL007034)
  • National Institute on Drug Abuse (44-D048712, 32HL007034)
  • National Heart, Lung, and Blood Institute (44-D048712, 32HL007034)
Topics
  • Social Sciences › Psychology › Applied Psychology › Digital Mental Health Interventions
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
Keywords
substance use disorders, COVID-19 pandemic, digital health interventions, chatbot therapy, alcohol consumption, cannabis use, substance use reduction, depression, anxiety, craving, user satisfaction
MeSH terms
COVID-19, SARS-CoV-2, Adult, Female, Humans, Male, Mental Health, Substance-Related Disorders, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review